Evidence map›Paper›PMID 28622967›Full record

ReviewClinica chimica acta; international journal of clinical chemistry2017

New markers of urinary tract infection.

Anna Masajtis-Zagajewska, Michal Nowicki

Registry-linked trialAbstract readReview
PubMed Publisher
In one paragraph

Review in Clinica chimica acta; international journal of clinical chemistry, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT04735042 (Use of Combination Empagliflozin/Linagliptin or Dapagliflozin/Saxagliptin vs Empagliflozin or Dapagliflozin Alone, Subclinical Inflammation of the Genito-urinary Tract and Risk of Infections.), which is not on this map. Cited by 41 papers.

0numbers the graph read from it
0cells of the map it votes in
41citing papers in PubMed
3.5field-weighted citation impact, top 7% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT04735042 completedstarted 2020, after this paper: background citation

Use of Combination Empagliflozin/Linagliptin or Dapagliflozin/Saxagliptin vs Empagliflozin or Dapagliflozin Alone, Subclinical Inflammation of the Genito-urinary Tract and Risk of Infections.

Ran2020Enrolled60Registered outcomes9Posted comparisons0ConditionsType 2 Diabetes, Urinary Tract InfectionsArmsEmpagliflozin / Linagliptin or Dapagliflozin/Saxagliptin Pill, Empagliflozin or Dapagliflozin Pill
PMID 29446523PMID 27862830PMID 28769579PMID 20539810PMID 20937688PMID 23967406PMID 24567764PMID 25140306PMID 25759592PMID 28588220PMID 29520146other papers from this trial
Open the trial in the graph
3 · Its place in the literature

Who cites it

41 citing papers in PubMed, 93 citations in OpenAlex.

  1. Review
  2. Clinical Applications of Extracellular Vesicles: Promises and Pitfalls.International journal of molecular sciences · 2026
    Review
  3. Article
  4. Article
  5. The Role ofInternational journal of molecular sciences · 2025
    Review
  6. Article
  7. Review
  8. Review
  9. Article
  10. Review
  11. Review
  12. Article
  13. Article
  14. Review
  15. Article
  16. Review
  17. Article
  18. Article
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

2 authors at 1 institution in 1 country.

Anna Masajtis-ZagajewskaDepartment of Nephrology, Hypertension and Kidney Transplantation, Medical University of Lodz, Central University Hospital and Teaching Center, Pomorska 251, 92-213 Lodz, Poland.
Michal NowickiDepartment of Nephrology, Hypertension and Kidney Transplantation, Medical University of Lodz, Central University Hospital and Teaching Center, Pomorska 251, 92-213 Lodz, Poland. Electronic address: nefro@wp.pl.
Medical University of Lodz · PL

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Urinary tract infection (UTI) is the most common bacterial infection independent of age. It is also one of the most common causes of hospitalizations for infections among elderly people and the most common indication for antibiotic prescriptions in primary care. Both diagnostics and management of lower and upper urinary tract infections provide challenges in clinical practice due to their high prevalence and recurrence, and worldwide increase of antibiotic resistance. The clinical symptoms of UTI are often uncharacteristic or asymptomatic. The accurate diagnosis and early treatment are crucial due to risk of septicaemia and long-term consequences. Currently the diagnosis of urinary tract infection is based on the presence of clinical symptoms in combination with the results of nitrite strip test indicating the presence of bacteria in urine and semi-quantitative measurement of white blood cells count in urine. Although urine culture is the gold standard in UTI diagnostics it is both time-consuming and costly. Searching for novel biomarkers of UTI has attracted much attention in recent years. The article reviews several promising serum and urine biomarkers of UTI such as leukocyte esterase, C-reactive protein, procalcitonin, interleukins, elastase alpha (1)-proteinase inhibitor, lactofferin, secretory immunoglobulin A, heparin-binding protein, xanthine oxidase, myeloperoxidase, soluble triggering receptor expressed on myeloid cells-1, α-1 microglobulin (α1Mg) and tetrazolium nitroblue test (TNB).

Indexed as

AnimalsBiomarkersHumansUrinary Tract InfectionsBiomarkersAcute pyelonephritisInflammation, biomarkersUrinary tract infection

Identifiers

PMID28622967
OpenAlexW2626823115

What Socratic holds

Textmetadata
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.